TCR gene therapy of spontaneous prostate carcinoma requires in vivo T cell activation

Moniek A de Witte, Gavin M Bendle, Marly D van den Boom, Miriam Coccoris, Todd D Schell, Satvir S Tevethia, Harm van Tinteren, Elly M Mesman, Ji-Ying Song, Ton N M Schumacher

Research output: Contribution to journalArticlepeer-review

39 Citations (Scopus)


Analogous to the clinical use of recombinant high-affinity Abs, transfer of TCR genes may be used to create a T cell compartment specific for self-Ags to which the endogenous T cell repertoire is immune tolerant. In this study, we show in a spontaneous prostate carcinoma model that the combination of vaccination with adoptive transfer of small numbers of T cells that are genetically modified with a tumor-specific TCR results in a marked suppression of tumor development, even though both treatments are by themselves without effect. These results demonstrate the value of TCR gene transfer to target otherwise nonimmunogenic tumor-associated self-Ags provided that adoptive transfer occurs under conditions that allow in vivo expansion of the TCR-modified T cells.
Original languageEnglish
Pages (from-to)2563-71
Number of pages9
JournalJournal of Immunology
Issue number4
Publication statusPublished - 15 Aug 2008


Dive into the research topics of 'TCR gene therapy of spontaneous prostate carcinoma requires in vivo T cell activation'. Together they form a unique fingerprint.

Cite this